Inbiopro is a biopharmaceutical company focusing on biologicals – process and product development – to deliver solutions that make a difference to enterprises and patients alike.
We leverage our comprehensive research-to-manufacture capabilities to forge strong partnerships with leading industry players. This helps us bring effective therapeutics to make treatment and care affordable in the areas of oncology, rheumatoid arthritis, and cardio vascular diseases, among others.
Our scientists develop, characterize, and validate biologicals (products and processes) with comprehensive research and clinical trials. This is complemented by our full-scale manufacturing proficiency in bacterial, yeast, and CHO platforms.
The Indian biopharma sector is uniquely poised to lead the new wave of global biosimilars development. It can draw from a robust infrastructure network, favorable regulations regime, and a trained talent pool to support drug discovery and manufacturing initiatives. Inbiopro taps these opportunities to produce treatment-altering biosimilars for varied markets.
Our research-to-manufacturing capabilities are complemented by our flagship partnership with Strides Arcolab’s wholly-owned subsidiary, Agila Specialities. This lets us gain from Strides’ tested commercial policies and established market presence in making our high-value product portfolio accessible to people through multiple commercialization options. It also aids in augmenting our already robust biologics pipeline, with more promising biosimilar candidates.
Inbiopro has a cumulative biotechnological, industrial, and hands-on experience of over 70 years, along with in-depth knowledge of several biologicals, including biosimilars and vaccines. We take a biological from R&D to manufacturing through the following: